Study wrapper · #437
Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome.
Editor's note
A single case report of a 31-year-old woman with Smith-Magenis syndrome, a rare neurodevelopmental disorder with hyperphagia-driven obesity, given tirzepatide titrated to 5 mg weekly. Over 10 months she lost 9.4% of her body weight (7.3 kg) with improved fasting glucose, and caregivers reported reduced food-seeking, less impulsivity and a measured reduction in aggression; the drug was described as well tolerated. This is a single patient, the weakest evidence tier, and the behavioral observations are caregiver-reported and open-label, highly susceptible to expectation effects. The metabolic changes are consistent with tirzepatide's known weight effects; the behavioral claims are intriguing but should be read as anecdote generating a hypothesis about central appetite and behavior pathways, not evidence of a neuropsychiatric benefit. Useful mainly as a first description in an ultra-rare population where no prior data existed.
Plain-language abstract
This is a report of one patient: a 31-year-old woman with Smith-Magenis syndrome, a rare genetic condition that causes intellectual disability, difficult behaviors and excessive eating leading to obesity. She had lifelong obesity and aggressive behaviors that had not responded to usual approaches. Her doctors started tirzepatide, a weekly injection, building up to 5 mg per week. Over ten months she lost about 9.4% of her weight (7.3 kg) and her fasting blood sugar improved. Her caregivers also noticed she sought food less, was less impulsive, and, by a formal measure, was less aggressive. The treatment was well tolerated. Because this describes just one person and the behavior changes were reported by caregivers who knew she was on the drug, the findings cannot be generalized and may partly reflect expectation. The authors suggest it points to a possible avenue worth investigating, since this drug had not previously been described in this condition.